Galera Therapeutics, Inc.
GRTX$4M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaMALVERN3 employees
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
GRTX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
GC4419 90mg
Oral Mucositis
GC4419
Pancreatic Cancer
Drug: GC4419
Head and Neck Cancer
Low Dose GC4419: 30mg/day
Radiation Induced Oral Mucositis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GC4419 90mg | Phase 3 | Oral Mucositis | - | - |
GC4419 | Phase 2 | Pancreatic Cancer | - | - |
Drug: GC4419 | Phase 2 | Head and Neck Cancer | - | - |
Low Dose GC4419: 30mg/day | Phase 2 | Radiation Induced Oral Mucositis | - | - |
Pancreatic Cancer
1 drug in this indication
Radiation Induced Oral Mucositis
1 drug in this indication
Oral Mucositis
1 drug in this indication
Head and Neck Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply